European Biopharmaceutical Review |
 |
|
|
|
|
 |
| |
|
|
|
|
Development and Production
Understanding the Bottlenecks Holding Back Biologics
What are the recent developments in biologics production, how have these developments been impacted by COVID-19, and what does the future hold for the sector?
Alex Page at Watson-Marlow
|
|
|
|
|
|
Rare Diseases
Pooling Efforts to Drive Gene Therapies for Rare Diseases
A three-pronged approach that will drive gene therapies to market in a more efficient and financially viable way, and then ultimately into the hands of patients. This requires improved collaboration across the biopharma industry.
Christian Schneider at Biopharma Excellence
|
|
|
|
|
|
Antimicrobial Resistance
The Balancing Act of Antimicrobial Technologies
The COVID-19 pandemic has led to a boom in antimicrobial products, bringing with it its own risks. With antimicrobial resistance a growing concern, navigating the future will be a complex task.
India Toomey and Nadia Tsao at IDTechEx
|
|
|
|
|
|
Cell and Gene Treatments
Beyond CAR T Cells: The Future of Adoptive Cell Therapies
Looking ahead towards the promising future of adoptive cell therapies, and identifying the challenges that lie in the way of them becoming the go-to treatment for cancer patients.
Marwan Alsarraj at Bio-Rad
|
|
|
|
Cell and Gene Therapy
Increasing the Accessibility of Life-Changing Treatments
The emergence and growth of cell and gene therapies means a potentially game-changing treatment for patients with a range of cancers and rare diseases. How can researchers in this area begin to overcome challenges and help them become a more affordable and accessible option?
Hilary Thomas, Anu Solanki, and Luca Pinton at PA Consulting.
|
|
|
|
Cell and Gene Treatments
Overcoming the Challenges of
Large-Scale Plasmid
Production
What are the difficulties faced
when dealing with plasm
production, and how will WuXi’s
recent acquisition of OXGENE
streamline the process of getting
important therapies to market?
|
|
|
|
Cell and Gene Treatments
Modelling Genetic Disease: iPS Cell Line Development Using Gene Editing
Deriving patient-specific cell lines that can be used to generate functional tissue for disease modelling, drug discovery, and screening is a worthwhile endeavour – and the right tools and strategies can minimise the required time and effort.
Amanda Haupt at Horizon Discovery, a PerkinElmer Company
|
|
|
|
|
|
Cell Culture
Exploring CO2 Incubator Technologies Designed for Cleanroom Cell Culturing
The laboratory manufacturers who are turning towards dedicated CO2 incubators in order to effectively cultivate novel cell-based therapies.
|
|
|
|
Cell Culture
A Pressing Need for Accurate Preclinical Models of Metabolic Disease
The technology that is revolutionising the way that we understand, and develop targeted biotherapeutics for, the modern epidemic of metabolic disease.
Dr Anthony Berger at CN Bio
|
|
|
|
|
Biomarkers
Dynamising Biomarker R&D with Smarter Biospecimens
In the midst of turmoil caused by the COVID-19 pandemic, what are the obstacles facing scientists looking to work with biospecimens and how can they be overcome?
Zara Puckrin, David Bunton, Graeme Macluskie, and Rachna Goyal at REPROCELL
|
|
|
|
|
|
Infectious Diseases
Finding the Signal Among the Noise – The Challenges of Flavivirus Serology
Despite flaviviruses representing a growing global health concern, means of diagnosis continue to suffer from low specificity and breadth – but what recent efforts have been made to improve them and what does the future hold for this vital research?
James Shore at The Native Antigen Company
|
|
|
|
Infectious Diseases
The Future of Vaccines for Infectious Diseases
How we can make better use of the often-overlooked power of cytotoxic T cells using arenaviruses in the development of vaccines for infectious diseases.
Klaus Orlinger, Henning Lauterbach, Daniel Pinschewer, and Igor Matushansky at HOOKIPA Pharma
|
|
|
|
Infectious Diseases
Diagnosing Emerging Variants of SARSCoV- 2 for Effective Transmission Control
With the Omicron variant increasing the spread of COVID-19 – just like the Delta variant before it – testing methods are in a constant race to keep up with the virus and its mutations.
David Wilson at Avacta
|
|
|
|
Infectious Diseases
A New Generation of Agents Combatting Antibiotic Resistance
The strain being put on the healthcare system by the increasing use of antibiotics in both medicine and agriculture has led to more innovative solutions to combat antibioticresistant bacteria.
Dr Heather Fairhead at Phico Therapeutics
|
|
|
|
Infectious Diseases
Bioelectronic Assay Identifies Potential COVID-19 Therapeutic Targets
It is essential that safe and effective treatments be found for COVID-19 as the world comes to terms with the long-term presence of the virus – and bioelectronic assays will be key moving forwards.
Jim Ross at Axion Biosystems
|
|
|
|
|
|
AI in Drug Discovery
The Rise of Machine Learning and What it Means For Biological and Chemical Data
Despite advances, there is still one bottleneck holding back more significant developments in drug discovery. What are the problems, and how should they be addressed?
Nil Adell-Mill at Arctoris
|
|
|
|
AI in Drug Discovery
Phenomics: What It Is and Why It Is the Future of Drug Discovery
The future of drug discovery has increasingly been pointing away from the tried-and-tested method of target-based screening and towards a more accurate and effective technique.
Stacie Calad-Thomson at BioSymetrics
|
|
|
|
AI in Drug Discovery
AI Does Not Drive Novel Drug Discovery, Science Does
The pharma industry is being touted as the next big beneficiary of the game-changing effects of AI. But where does it fit in within the overall process of drug discovery?
Andrew Radin at Aria Pharmaceuticals
|
|
|
|
|
|
Academia and Pharma
Unravelling New Disease Biology at the Interface Between Academia and the Pharma Industry
Drug development is a lucrative business, but breakthrough innovations are just as important for healthcare. How can different perspectives lead to key advances in research and development?
Christian Tidona at BioMed X Institute
|
|
|
|
|
|
Biomaterials
Biomaterials: Challenges, Characteristics, and Considerations
The diverse range of uses of biomaterials, and the difficulties, challenges and considerations that play a part in their clinical development.
Dr Jeff Daelman at Rousselot
|
|
|
|
|
|
